Research Article

LncRNA MBNL1-AS1 Represses Proliferation and Cancer Stem-Like Properties of Breast Cancer through MBNL1-AS1/ZFP36/CENPA Axis

Yu Ding,1 Yingjie Li,2 Yunqiang Duan,1 Wan Wang,3 Wei Zheng,4 Weilun Cheng,1 Yuan Qi,1 Jianyuan Feng,1 Ziang Chen,1 Tianshui Yu,1 Anbang Hu,1 Ting Wang,1 Mingcui Li,1 Hanyu Zhang,1 Yanling Li,1 Fei Ma,1 and Baoliang Guo1

1Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
2Department of Pathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
3Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
4Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

Correspondence should be addressed to Fei Ma; wafsfd@sina.com and Baoliang Guo; baoliangguo2013@163.com

Received 19 October 2021; Revised 12 March 2022; Accepted 30 March 2022; Published 26 April 2022

Academic Editor: Vinay Sagar

Copyright © 2022 Yu Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Emerging studies have revealed long noncoding RNAs (lncRNAs) were key regulators of cancer progression. In this research, the expression and roles of MBNL1-AS1 were explored in breast cancer (BC).

Methods. In this study, the MBNL1-AS1 expression in breast cancer tissue, as well as in cell line, was studied by qRT-PCR assays. The effects of MBNL1-AS1 on proliferation and stemness were evaluated by MTT assays, colony formation assays, orthotopic breast tumor mice models, extreme limiting dilution analysis (ELDA), fluorescence in situ hybridization (FISH), flow cytometry assays, and sphere formation assays. Flexmap 3D assays were performed to show that MBNL1-AS1 downregulated the centromere protein A (CENPA) secretion in BC cells. Western blot, RNA pull-down assays, RNA immunoprecipitation (RIP) assays, and FISH were conducted to detect the mechanism.

Results. The results showed that the expression levels of MBNL1-AS1 were downregulated in breast cancer tissues and cell lines. In vitro and in vivo studies demonstrated that overexpression of MBNL1-AS1 markedly inhibited BC cells proliferation and stemness. RNA pull-down assay, RIP assay, western blot assay, and qRT-PCR assay showed that MBNL1-AS1 downregulated CENPA mRNA via directly interacting with Zinc Finger Protein 36 (ZFP36) and subsequently decreased the stability of CENPA mRNA. Restoration assays also confirmed that MBNL1-AS1 suppressed the CENPA-mediated proliferation and stemness in breast cancer cells. Conclusions. The new mechanism of how MBNL1-AS1 regulates BC phenotype is elucidated, and the MBNL1-AS1/ZFP36/CENPA axis may be served as a therapeutic target for BC patients.

1. Introduction

Female breast cancer has surpassed lung cancer as the most common cancer, with about 2.3 million new cases (11.7%) [1]. It is the main cause of cancer-associated death for women around the world [2]. Approximately 15.4% of women died of breast cancer, although the diagnosis and treatment strategies improved greatly over the past several decades [1]. The abnormal proliferation of tumor cells is a striking feature of malignant tumors. Cancer stem cells (CSCs) have vital roles in intra- and intertumoral heterogeneity, which are related to tumor progression, treatment resistance, and disease relapse [3, 4]. Therefore, exploring the potential molecular mechanisms underlying breast cancer proliferation and stemness is of paramount importance in identifying effective and novel therapeutic strategies.

LncRNAs, classes of noncoding RNAs (ncRNAs), have greater than 200 nucleotides length [5, 6], and were able to modulate several phenotypes such as proliferation, metastasis, stemness, and progression of cell cycle [7–10].
Table 1: The primer sequences of qRT-PCR used in this study.

| Name       | Forward          | Reverse          |
|------------|-----------------|-----------------|
| MBNL1-AS1  | CTCCCGCTTCTTCTACCCGAC | TTGGTGCAATTATTAAGCCGCC |
| ZFP36      | TCCACAACCTAGGGAAGAC | GAGAAGGCCAGGAGTGACAG |
| CENPA      | GATCTCTGGAATGTGCTG  | GCCTTTGGAACGGTGTT |
| GAPDH      | TTCCCTACCTTGGACCTTG | TCTCTTTGCTCCTTGGT |

Accumulating researches had showed that the expression pattern of lncRNAs was correlated with cancer progression, proliferation, and stemness [10–13]. Emerging evidence demonstrated that lncRNAs regulated the expression level of a target gene by binding to RNA-binding proteins (RBPs). For instance, the lncRNAs interacted with the RBPs and subsequently regulated cancer progression [14, 15]. These researches showed that lncRNAs were pivotal players in cancer pathogenesis and vital new biomarkers in cancer early detection and therapy. Recently, two cohorts were analyzed and lncRNAs of different expression by research in BC. MBNL1-AS1 was regarded as one of the downregulated lncRNAs in BC [13]. However, the phenotype and mechanism of MBNL1-AS1 in BC have not been detected.

CENPA (a 17 kDa variant of histone H3) was located in the active centromeres [16, 17]. A previous study has found that CENPA was correlated with human pluripotent stem cell self-renewal [18]. Low expression of CENPA induced cell cycle arrest and promoted apoptosis [19]. Subsequent evidence showed that upregulation of CENPA promoted initiation and progression in several cancers [17, 20]. Higher expression of CENPA was correlated with increased invasiveness and higher-grade cancers [19, 21]. In contrast, downregulation of CENPA showed to inhibit the HCC cells proliferation [19]. Moreover, CENPA had predictive value in breast cancer and could contribute to disease progression as a marker of proliferation [21, 22]. In this research, MBNL1-AS1 was found markedly decreased the expression of CENPA mRNA.

Here, the study showed that MBNL1-AS1 in BC was downregulated and the decreased expression of MBNL1-AS1 was correlated with survival. MBNL1-AS1 inhibited BC proliferation, and stem cell properties were confirmed by functional studies in vitro and in vivo. Mechanistically, MBNL1-AS1 directly interacted with ZFP36, an RNA-binding protein, subsequently reduced the stabilization of CENPA mRNA. This study might bring new insights into therapeutic targets for BC.

2. Materials and Methods

2.1. Cell Lines and Human BC Specimens. Human BC cell lines (MCF-7, MDA-MB-468, and MDA-MB-231) and the immortalized normal breast cell line MCF-10A were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Indicated cells were cultured in DMEM containing 10% FBS (Thermo Fisher Scientific) and were supplied at 37°C in a humidified atmosphere of 5% CO₂. 60 BC specimens were obtained from the Department of Breast Surgery, The Second Affiliated Hospital of Harbin Medical University (246 Xuefu Street, Nangang District, Harbin, China). The 60 patients were Asian women, aged from 33 to 77 years. Fresh BC tissues and paired adjacent normal tissues were frozen in liquid nitrogen immediately after surgical excision and saved at -80°C. The tissues were validated by H&E staining. This research was approved by the Ethics Committee of Harbin Medical University.

2.2. qRT-PCR Assay. To isolate total RNA, the TRIzol reagent (Life Technologies, Carlsbad, CA, USA) was performed. Next, DNase Treatment was used to remove genomic DNA. It was performed as previously detailed described [23]. For cDNA synthesis, the total RNA was retrotranscribed with the PrimeScript™ RT Reagent Kit (Takara). The SYBR Premix Ex Taq™ Kit (Takara, Tokyo, Japan) was utilized to carry out qPCR. And RT-PCR was conducted on a 7500 RealTime PCR System. GAPDH was measured as the internal control. The sequences of the primers that were used are as follows: for MBNL1-AS1: 5′- CTCCCCGCTTCTCTACCCGAC-3′ (forward), 5′- TTTGGTGCAATTATTAAGCCGCC-3′ (reverse); for CENPA: 5′- GATCTCTGGAATGTGCTG-3′ (forward), 5′- GCCTTTGGAACGGTGTT G TT-3′ (reverse); for ZFP36: 5′- TCCACAACCTAGGGAAGAC -3′ (forward), 5′- GAGAAGGCCAGGAGTG TGTTTTTA-3′ (reverse); for GAPDH: 5′- TTCCCTACCTTGGACCTG-3′ (forward), 5′- TCTCTTTGCTCCTTGGC TCGTGGTGCATTTTAA GGGC GG -3′ (reverse); for GAPDH: 5′- GCCTTTGGAACGGTGTT GTT TTGGTGCATTTTAA GGGC GG -3′ (reverse); for GAPDH: 5′- GCCTTTGGAACGGTGTT GTT TTGGTGCATTTTAA GGGC GG -3′ (reverse); for GAPDH: 5′- GCCTTTGGAACGGTGTT GTT TTGGTGCATTTTAA GGGC GG -3′ (reverse); for GAPDH: 5′- GCCTTTGGAACGGTGTT GTT TTGGTGCATTTTAA GGGC GG -3′ (reverse).

2.3. Cell Transfection. To assess the MBNL1-AS1 overexpression vector, the lentiviral vector-MBNL1-AS1 and lentiviral vector-convirus (GenePharma, Shanghai, China) were transfected in cells. sh-MBNL1-AS1#1, sh-MBNL1-AS1#2, and sh-control were obtained from GenScript (Nanjing, China). The qRT-PCR assays were used to detect the expression of MBNL1-AS1. The sequences of the MBNL1-AS1 targeting shRNAs were as follows: for MBNL1-AS1-shRNA#1: 5′- GTTCTGGAAGAAGAGCCGGTTTTCAGAGAATACCTGCTTCTCTTGGTTTTTTTA-3′ (sense), 5′- GTTCTTAAAAAAACGAGAAAAGGAGGTATTCTCTCTGGAAATACCTGCTTCTCTTGGTTTTTTTA-3′ (antisense); for MBNL1-AS1-shRNA#2: 5′- GTTCTGGAAGAAGAGCCGGTTTTCAGAGAATACCTGCTTCTCTTGGAAATACCTGCTTCTCTTGGTTTTTTTA-3′ (antisense); for MBNL1-AS1-shRNA#3: 5′- GTTCTTAAAAAAACGAGAAAAGGAGGTATTCTCTCTGGAAATACCTGCTTCTCTTGGTTTTTTTA-3′ (antisense). siRNA, si-ZFP36, and si-NC were obtained from RiboBio (Shanghai, China). The
sequences are listed in Table 2. Lipofectamine 2000 (Invitrogen) was used for the transfections of shRNAs and siRNAs in breast cancer cells. The cells were harvested 48 h after transfection for RNA extraction or functional assays.

2.4. MTT Study. Transfected cells were seeded in a 96-well plate (Corning Life Science) which had 3 × 10^3 cells/well. Each well was added with 10 μL MTT (5 mg/mL) for different periods of time. After 4 hours of incubation, 150 μL of dimethyl sulfoxide was added to dissolve the precipitates. The absorbance was then measured by detection at 560 nm using a microplate reader. The experiment was performed independently in triplicate.

2.5. Colony Formation Analysis. The BC cells were harvested and plated in a 6-well plate (0.2 × 10^3 cells/well) and cultured in incubators. After 14 days of culture, the plate was washed 3 times with PBS. The indicated BC cells were dried and stained with 0.1% crystal violet solution at 37°C for 15 minutes. Then, the cell colonies formed were numbered under a digital camera.

2.6. Sphere Formation Assay. A total of 5 × 10^3 cells were plated in 6-well ultralow attachment surface plates (Corning Life Science). EGF (20 ng/mL, Invitrogen), bFGF (10 ng/mL, Invitrogen), and 2% B27 (Invitrogen, Carlsbad, CA) were formulated in a medium. After 2 weeks, the number of spheroids was counted manually by a microscope.

2.7. Extreme Limiting Dilution Assay. Extreme limiting dilution assay was performed as previously described [24]. Briefly, MCF-7 or MDA-MB-231 cells were plated in 96-well ultralow attachment surface plates at a density of 100, 250, 500, and 1000 cells/well, with 12 replicates for each cell density at 37°C in a humidified atmosphere of 5% CO_2. The number of wells presenting visible tumor spheres was counted on after 14 days, and then the data was put into the ELDA online software (http://bioinf.wehi.edu.au/software/elda/). The stem cell frequency was calculated.

2.8. Flow Cytometry Assay. Flow cytometry assay was performed as previously described [25, 26]. Briefly, using flow cytometry with the use of propidium iodide (Sigma-Aldrich, MO China) staining (5 μg/mL), cell cycle analysis was performed after transfection. The cells were trypsinized and dispersed into cell suspension. Next, 1 mL of cell suspension was centrifuged at 1,500 rpm for 10 min. Then, the indicated cells were added with chilled ethanol and saved at 4°C overnight. Then, the BC cells were centrifuged and resuspended in PBS and appended with 100 μL RNase at room temperature. After 30 min, 100 μL PI was appended, and cells were incubated at 37°C in dark for 60 minutes. Cell cycle was determined by FACScaliber Flow Cytometer. MCF-7 and MDA-MB-231 cells were labeled with FITC-conjugated CD44 antibody and PE-conjugated CD24 antibody at 4°C, using 5 μg/mL, cell cycle analysis was performed. The cells were trypsinized and dispersed into cell suspension. Next, 1 mL of cell suspension was centrifuged at 1,500 rpm for 10 min. Then, the indicated cells were added with chilled ethanol and saved at 4°C overnight. Then, the BC cells were centrifuged and resuspended in PBS and appended with 100 μL RNase at room temperature. After 30 min, 100 μL PI was appended, and cells were incubated at 37°C for 15 min. Data were analyzed with a FACS Aria II cell sorter (BD, Bioscience, USA).

2.9. Western Blot. Total protein of indicated cells was extracted using RIPA lysis buffer (Beyotime, Jiangsu, China) with protease inhibitors. Cell lysates were separated on 10% SDS-PAGE. A PVDF membrane was transferred by the indicated protein, which was blocked with 5% non-fat dry milk. Primary antibodies, namely, Ab against ZFP36 (1:1000), and Ab against GAPDH (1:1000) (all from Thermo Fisher Scientific, USA), were incubated with the membrane. Subsequently, the secondary antibodies (1:10000) (Thermo Fisher Scientific, USA) were incubated with the membrane for 1 h. After developed by enhanced chemiluminescent and exposure, immunoreactive protein band intensities were analyzed by Image J software.

2.10. RNA Pull-Down. The biotin-labeled MBNL1-AS1 plasmid and biotin-labeled antisense RNA plasmid were, respectively, transfected in BC cells. Biotin-labeled RNA was bound to the Streptavidin agarose Beads, next mixed with indicated cell lysates. Indicated bound RNAs were isolated from the beads by washed and boiled for normal western
Figure 1: Continued.
The assays were experimented in RNase-free conditions.  

2.11. RNA Immunoprecipitation (RIP) Assay. RIP was performed with the use of the Magna RIP kit (Millipore, USA). The spectrophotometer (Thermo Scientific, USA) was used to examine the RNA concentration, and the bioanalyzer (Agilent, USA) was utilized to detect the RNA quality. The input control was the total RNA. Following, qRT-PCR analysis was used to test the results to demonstrate the bound targets.

2.12. Magnetic Luminex® Performance Assay. Magnetic Luminex® performance assay was performed based on our previous study [14]. Briefly, NC or MBNL1-AS1 was transfected in MDA-MB-231 cells, which were incubated for 1 day. Following centrifugation, the supernatant was collected. Then, the following human cytokines: PLK1, PAF, CENPA,
Table 3: Relationship between MBNL1-AS1 expression and clinicopathologic features of BC patients (n = 60).

| Variable                     | Relative MBNL1-AS1 expression | P-value |
|------------------------------|-------------------------------|---------|
|                              | Low (n=30) | High (n=30) |
| Age                          |           |             |
| <50                          | 16        | 13         |
| >50                          | 14        | 17         |
| Histological differentiation |           |             |
| Well                         | 9         | 13         |
| Moderate                     | 12        | 12         |
| Poor                         | 9         | 5          |
| Tumor size                   |           |             |
| <2 cm                        | 8         | 17         |
| 2-5 cm                       | 11        | 6          |
| >5 cm                        | 11        | 7          |
| Lymph node metastasis        |           | P<0.05    |
| Yes                          | 18        | 9          |
| No                           | 12        | 21         |
| Tumor stage                  |           | P<0.05    |
| I                            | 6         | 16         |
| II                           | 13        | 9          |
| III                          | 11        | 5          |

Note: BC patients were divided into MBNL1-AS1 high group and low group according to the analysis of qRT-PCR detection. NS: not significant between different groups. Differences among variables were evaluated by χ² or Fisher’s exact χ²-test.

YB-1, TWIST, YY1, KLF4, CUG2, E2F8, SALLA, RAE1, and PTPA were analyzed by FlexMAP 3D (Luminex®) platform.

2.13. Immunofluorescence Staining (IF) and Fluorescence In Situ Hybridization (FISH) Assay. IF and FISH assays were performed as previously described [14, 26]. For FISH, the MBNL1-AS1 subcellular localization was assessed by the lncRNA FISH Probe Mix and FISH kit which was obtained from Guangzhou RiboBio Co., Ltd. The 4% paraformaldehyde-fixed cells were fixed in PBS. After washed by phosphate buffered solution with tween for three times, the anti-fluorescence quencher sealed the indicated cells, and the images were taken by the FV1000 laser microscope (Olympus, Japan). For IF, cells were fixed with 4% formaldehyde and subjected to standard immunofluorescence staining. The anti-CENPA and secondary antibodies were obtained from Thermo Fisher Scientific. The data was analyzed by Image J software. The nuclei were dyed with DAPI. The 3D-cultured spheroids were conducted as previously described [26].

2.14. mRNA Decay Assay. Stable cells were added with 5 µg/mL actinomycin D. Following, qRT-PCR was performed to determine the CENPA mRNA. The data was performed independently in triplicate.

2.15. Animal Studies. Animal studies were ratified by the ethics committee of Harbin Medical University (Harbin, China). The BC cells were injected in the flank of four-week-old female nude mice (each group has 3 mice). The volume of tumor was recorded every week. After intraperitoneal injection of D-luciferin, all mice were imaged by the Xenogen IVIS Spectrum Imaging System (Caliper Life Sciences, USA) before being sacrificed. Primary tumor volume was measured. The mice were euthanized by i.p. injection of sodium pentobarbital (200 mg/kg).

2.16. Statistical Analysis and Database. All analyses were experimented three times at least. The measurement data in this study were exhibited as means ± SD. Student’s t-test was applied to compare the numeric variables between two groups. The differences between more than two groups of variables were evaluated by χ² or Fisher’s exact χ²-test. R software package version 3.0.0 and GraphPad Prism 5 were used. The TCGA data set from the GEPIA2 Platform was used to analyze the expression of MBNL1-AS1 in tumor and normal tissues. And Kaplan-Meier Plotter was used to analyze the expression of MBNL1-AS1, InLocater database (http://www.csbio.sjtu.edu.cn/bioinf/InLocater/) was used to predict the subcellular localization of MBNL1-AS1. A p-value<0.05 was regarded as significant; p-value <0.01 was very significant.

3. Results

3.1. MBNL1-AS1 Expression Was Downregulated in BC Cells Which Was Correlated with Poor Prognosis. MBNL1-AS1 was regarded as one of the LncRNA suppressor genes associated with breast cancer, according to the bioinformatics analysis [13]. However, expression and function in breast tissue have not been confirmed yet. Therefore, the MBNL1-AS1 expression was detected in the cancer genome atlas (TCGA) database. As indicated in Figure 1(a), the MBNL1-AS1 expression pattern was marked lower than normal tissues in BC tissues. The MBNL1-AS1 levels in different BC subtypes were explored for the following study. The MBNL1-AS1 levels in tumor tissues were found markedly decreased in HER2+, Luminal A, and Luminal B subtypes compared with normal tissues. However, no statistical significance of MBNL1-AS1 expression was found in basal-like subtype between tumor tissues and normal tissues (Figure 1(b)). Next, the MBNL1-AS1 expression level was examined in 60 BC tissues and normal breast tissues. The H&E staining of the BC patients and normal sample is shown in Supplementary Figure 1A. Through the qRT-PCR, MBNL1-AS1 expression significantly decreased in the BC tissues (Figure 1(c)). Then, we linked the expression of MBNL1-AS1 with the clinicopathological features of the BC patients. We observed that the expression of MBNL1-AS1 had negative relationship with TNM stage and lymph node metastasis (Figure 1(d) and Table 3). Then, we detected the MBNL1-AS1 expression in several BC cell lines. Compared with the immortal MCF-10A cells and low-metastatic BC cell line MCF-7, the MBNL1-AS1 expression levels were observed to be much lower in BC cell lines, particularly in MDA-MB-468 and MDA-MB-231 cell lines with the higher metastatic features (Figure 1(e)).
Figure 2: Continued.
Figure 2: Continued.
Confidence intervals for 1/(stem cell frequency) \( P < 0.01 \)

| Group         | Lower | Estimate | Upper |
|---------------|-------|----------|-------|
| sh-NC        | 1502  | 923      | 567   |
| sh-MBNL1-AS1#1 | 608   | 401      | 265   |

Confidence intervals for 1/(stem cell frequency) \( P < 0.01 \)

| Group         | Lower | Estimate | Upper |
|---------------|-------|----------|-------|
| NC            | 684   | 450      | 296   |
| MBNL1-AS1     | 1717  | 1036     | 625   |

(c) MDA-MB-231 3D spheroids

(f) Figure 2: Continued.
Figure 2: Continued.
Given this expression mode, MCF-7 and MDA-MB-231 cell lines were selected to perform the following functional study. The Kaplan-Meier Plotter was used to make clear the relationship between the expression levels of MBNL1-AS1 and the patients' survival. The samples were grouped into high or low MBNL1-AS1 expression by median. The results showed that lower MBNL1-AS1 expression was markedly correlated to worse relapse-free survival (RFS) (Figure 1(f)). Altogether, the results demonstrated that the downregulated MBNL1-AS1 in BC might associate with a poor prognosis.

3.2. MBNL1-AS1 Inhibited Proliferation and Stemness of BC In Vitro and In Vivo.
The biological functions of MBNL1-AS1 in BC were examined by observing the relationship between the expression levels of MBNL1-AS1 and the patients' survival. The samples were grouped into high or low MBNL1-AS1 expression by median. The results showed that lower MBNL1-AS1 expression was markedly correlated to worse relapse-free survival (RFS) (Figure 1(f)). Altogether, the results demonstrated that the downregulated MBNL1-AS1 in BC might associate with a poor prognosis.

3.2. MBNL1-AS1 Inhibited Proliferation and Stemness of BC In Vitro and In Vivo.
The biological functions of MBNL1-AS1 in BC were examined by observing the relationship between the expression levels of MBNL1-AS1 and the patients' survival. The samples were grouped into high or low MBNL1-AS1 expression by median. The results showed that lower MBNL1-AS1 expression was markedly correlated to worse relapse-free survival (RFS) (Figure 1(f)). Altogether, the results demonstrated that the downregulated MBNL1-AS1 in BC might associate with a poor prognosis.

3.2. MBNL1-AS1 Inhibited Proliferation and Stemness of BC In Vitro and In Vivo.
The biological functions of MBNL1-AS1 in BC were examined by observing the relationship between the expression levels of MBNL1-AS1 and the patients' survival. The samples were grouped into high or low MBNL1-AS1 expression by median. The results showed that lower MBNL1-AS1 expression was markedly correlated to worse relapse-free survival (RFS) (Figure 1(f)). Altogether, the results demonstrated that the downregulated MBNL1-AS1 in BC might associate with a poor prognosis.

3.2. MBNL1-AS1 Inhibited Proliferation and Stemness of BC In Vitro and In Vivo.
The biological functions of MBNL1-AS1 in BC were examined by observing the relationship between the expression levels of MBNL1-AS1 and the patients' survival. The samples were grouped into high or low MBNL1-AS1 expression by median. The results showed that lower MBNL1-AS1 expression was markedly correlated to worse relapse-free survival (RFS) (Figure 1(f)). Altogether, the results demonstrated that the downregulated MBNL1-AS1 in BC might associate with a poor prognosis.
Figure 3: Continued.
significantly inhibited the CENPA secretion; however, other proteins were not of statistical significance (Figures 3(a) and 3(b)). We, therefore, set out to detect the regulatory effect of MBNL1-AS1 on CENPA in BC cells. Interestingly, MBNL1-AS1 significantly reduced the levels of CENPA protein and mRNA in BC cell lines (Figures 3(c) and 3(d)). Since the subcellular location of lncRNAs determined the functions, lncLocator database (http://www.csbio.sjtu.edu.cn/bioinf/lncLocator/) was used to predict the subcellular localization of MBNL1-AS1 (Figure 3(e)). The result showed that MBNL1-AS1 localized mainly in cytoplasm. We further confirmed that by FISH assay (Figure 3(f)), implying that CENPA might be regulated in a post-transcriptional manner.

As shown in Figure 3(f) and Supplementary Figure 2D, MBNL1-AS1 knockdown markedly upregulated the CENPA expression in MCF-7 cells and vice versa in other cell lines. We next detected whether or not MBNL1-AS1 regulated the CENPA mRNA in breast cancer cells. As expected, after the treatment of actinomycin D (an RNA synthesis inhibition agent), the CENPA mRNA half-life in MBNL1-AS1-silenced MCF-7 cells was dramatically prolonged while the CENPA mRNA half-life shortened after MBNL1-AS1 was transferred to MDA-MB-231 cells (Figure 3(g)). In conclusion, MBNL1-AS1 inhibited the CENPA expression by reducing the stability of CENPA mRNA.

Figure 3: MBNL1-AS1 inhibited the expression of CENPA by reducing the stability of CENPA mRNA. The proliferation- and stemness-associated factors were detected and shown by Flexmap liquichip assays (a) and the heat map (b). The expression levels of CENPA in the BC cells were tested by western blot assays (c) and qRT-PCR (d). (e) lncLocator database was used to predict the subcellular localization of MBNL1-AS1. (f) Subcellular localization in indicated cells was examined by combined IF/FISH assays. Scale bars =10 μm. (g) The abundance of CENPA in indicated cells treated with actinomycin D was detected by qRT-PCR. Experiments were performed independently in triplicate. *P < 0.05, **P < 0.01.
Figure 4: Continued.
Figure 4: MBNL1-AS1 interacted with ZFP36 and reduced the CENPA mRNA stability. (a) RIP assays and (b) RNA pull-down assays were used to examine the combination of MBNL1-AS1 and ZFP36 in MCF-7 and MDA-MB-231 cells. (c) The expression of ZFP36 and CENPA were detected using western blot. (d) qRT-PCR assays were performed to examine the half-life of CENPA mRNA in the BC cells. The data was performed independently in triplicate.
Figure 5: Continued.
Figure 5: Continued.
Figure 5: Continued.
3.4. MBNL1-AS1 Directly Interacted with ZFP36 and Subsequently Reduced the Stability of CENPA mRNA. To investigate how MBNL1-AS1 regulated CENPA, the RBPDB software was used to predict target proteins of MBNL1-AS1. ZFP36 was found that could directly bind with MBNL1-AS1. Besides, researches showed that ZFP36 can specifically bind to AU-rich elements (ARE) in the mRNA 3′UTR and subsequently induce mRNA decay [27, 28]. RIP assays were used to examine whether MBNL1-AS1 was physically associated with ZFP36. As indicated in Figure 4(a), these results demonstrated that MBNL1-AS1 could bind directly with ZFP36 in indicated cells. RNA pull-down analysis further demonstrated the interaction of MBNL1-AS1 and ZFP36. ZFP36 proteins were pulled down by MBNL1-AS1, but the antisense RNA was not pulled down (Figure 4(b)). To examine whether MBNL1-AS1 bound to ZFP36 and modulated the CENPA mRNA stability, we tested the CENPA mRNA half-life in indicated cells after ZFP36 was silenced. Before that, western blot assay was used to examine the ZFP36 knockdown efficiency in the BC cells (Figure 4(c)). As shown in Figures 4(c) and 4(d), MBNL1-AS1 could not affect the CENPA mRNA stability after ZFP36 silenced, nor decrease the protein pattern of CENPA in indicated cells. To conclude, MBNL1-AS1 directly interacted with ZFP36 and reduced the CENPA mRNA stability.

3.5. MBNL1-AS1 Suppressed Proliferation and Stemness of Breast Cancer Cells by Interacting with ZFP36. To further validate our findings, MTT assays, colony formation assays, and sphere formation assays were performed to examine the function of ZFP36 in breast cancer cell lines and xenograft tumor models. ZFP36 knockdown significantly enhanced the growth of MCF-7 cells; however, knockdown of MBNL1-AS1 did not revert the proliferation abilities (Figures 5(a) and 5(b)). The same results also showed that MBNL1-AS1 overexpression did not affect the growth of MDA-MB-231 cells after ZFP36 knockdown. Next, we examined the stemness abilities of indicated cells. As indicated in Figure 5(c), ZFP36 knockdown enhanced the stemness abilities of MCF-7 cells. However, knockdown of MBNL1-AS1 did not revert the stemness abilities of indicated cells. Similarly, sphere formation assays showed that MBNL1-AS1 knockdown or overexpression failed to revert the increase of sphere numbers in si-ZFP36 transfected BC cells. Meanwhile, the results of in vivo assays also confirmed that transfection of MBNL1-AS1 or si-MBNL1-AS1 did not revert the tumorigenic abilities after ZFP36 knockdown in orthotopic breast cancer mice models (Figure 5(d)). Our data revealed that the interaction of MBNL1-AS1 and ZFP36 inhibited the proliferation and stemness of BC cells.

4. Discussion

LncRNAs are known as diagnostic markers for several kinds of cancers including BC. Previous research demonstrated various lncRNAs as vital players in BC progression [13, 26]. In this research, the MBNL1-AS1 expression in breast cancer patients and its functions in BC cells were detected and investigated. The results indicated that expression of MBNL1-AS1 markedly decreased in breast cancer and high-metastatic BC cell lines, which was in line with the studies that revealed that MBNL1-AS1 levels were downregulated in colorectal cancer, NSCLC, retinoblastoma, and bladder cancer. Consistent with our research, another report showed that MBNL1-AS1 inhibited progression of NSCLC by sponging miR-135a-5p, which also identified MBNL1-AS1 as a tumor suppressor factor [29]. Also in NSCLC, a study revealed an inhibitory role of MBNL1-AS1 in CSC drug resistance of NSCLC by upregulating miR-301b-3p-targeted TGFBR2 [30]. Similarly, MBNL1-AS1 inhibited proliferation of bladder cancer through MBNL1-AS1/MiR-362-5p/QKI and MBNL1-AS1/miR-135a-5p/phlp2/foxo1 signaling pathway [31, 32]. The similar mechanism occurs in colon cancer; the study revealed an inhibitory role of MBNL1-AS1 by upregulating miR-412-3p-targeted MYL9 [33]. MBNL1-AS1/miR-338-5p/wnt/β-catenin signaling pathway also showed the anti-tumor effect in retinoblastoma [34]. These strongly demonstrated that MBNL1-AS1 might be a reliable biological marker to diagnose BC. The clinical significance of MBNL1-AS1 still needs to be further verified in more samples for the limitations of the present study. Moreover, MBNL1-AS1 inhibited the proliferation and...

![Figure 5: MBNL1-AS1 suppressed proliferation and stemness abilities of BC cells by interacting with ZFP36. MTT assay (a) and colony formation assay (b) were performed to measure the proliferation of MCF-7 cells and MDA-MB-231 cells. (c) Sphere formation assay was performed to analyze the stemness numbers and diameters of indicated cells. (d) Orthotopic breast tumor mice models were used to explore the growth of breast tumors. Tumor diameters were evaluated every week. (e) The MBNL1-AS1/ZFP36/CENPA axis regulated proliferation and stemness in BC cells and then affected BC progression. Experiments were performed independently in triplicate.](image-url)
stemness of breast cancer cells in vitro and inhibited the tumorigenesis of breast cancer cells in vivo as demonstrated by these results of gain- or loss-of-function studies. These results indicated that MBNL1-AS1 played antioncogenic roles in BC.

Mounting evidence showed that lncRNAs regulated the downstream gene expression by binding to RBPs and competing endogenous RNAs (ceRNAs) [14, 26, 35, 36]. ZFP36 was known as RBP, which bound to the target mRNAs untranslated regions subsequently reduced their stability [35, 37–39]. It was studied that the ZFP36 expression was downregulated in BC and regulated the stability of CENPA mRNA [38]. However, the upstream regulating factors except ZFP36 are still being researched. Our study demonstrated that the ability of ZFP36 to modulate the stability of CENPA mRNA was regulated by MBNL1-AS1. One research reported that the AP1 transcriptional factor components, including JUN, could transcriptionally regulate the expression of ZFP36 [40]. To clear if MBNL1-AS1 regulates the expression of ZFP36, so, we conducted western blot assays. The results showed that MBNL1-AS1 failed to regulate ZFP36 expression (Supplementary Figure 3A). The data could strengthen our hypothesis that MBNL1-AS1 interacts with ZFP36 and promotes the function of ZFP36 as an RNA-binding protein. MBNL1-AS1 directly interacted with ZFP36 and subsequently reduced the stabilization of CENPA mRNA. Similar regulatory mechanisms were also found in previous studies [35, 41]. In this research, the stability of CENPA mRNA was modulated by MBNL1-AS1 (Figure 3(a) and Figure 3(f)). Interestingly, in Figure 3(a), PLK1, PAF, YB-1, TWIST, YY1, KLF4, and SALL4 expressions were decreased but with no statistical significance in MBNL1-AS1 transfected cells. We find that MBNL1-AS1 has been reported to inhibit the progression of prostate cancer by sponging miR-181a-5p and regulating PTEN/Pi3K/AKT/mTOR signaling [42] and PTEN signaling happens to be regulated by PLK1, PAF, YB-1, TWIST, YY1, KLF4, and SALL4 [43–48]. Therefore, PLK1, PAF, YB-1, TWIST, YY1, KLF4, and SALL4 might be the indirect downstream targets of MBNL1-AS1. As for CUG2, E2F8, RAE1, and PTPA, they were reported to be the downstream targets of several other factors, like NPM1, NONO, NKG2D, and UBE3A [49–52]. So, CUG2, E2F8, RAE1, and PTPA might not be the downstream targets of MBNL1-AS1 in breast cancer cells. Therefore, they may remain unchained. However, the possibility of translation of the MBNL1-AS1 control CENPA mRNA has not yet been detected. Thus, further study is still needed to the development of how MBNL1-AS1 regulated the CENPA expression.

MBNL1-AS1 was regarded as one of the tumor suppressors of lncRNAs in BC [13]. Nevertheless, no studies had confirmed the MBNL1-AS1 expression pattern in BC. Therefore, the expression pattern of MBNL1-AS1 was detected for the first time in breast cancer tissues and cell lines. MBNL1-AS1 was confirmed that the expression in breast cancer and highly metastatic cells was downregulated. That result was consistent with the bioinformatic data from TCGA. In functional assays, an anti-stemness and anti-proliferation function of MBNL1-AS1 was shown by decreasing CENPA expression. In accordance with our study, the researchers also confirmed that MBNL1-AS1 was a tumor-suppressive lncRNA [29, 31–34]. We demonstrated that MBNL1-AS1 attenuated the abilities of breast cancer stemness and proliferation through reduced stability of CENPA mRNA, which unraveled a novel mechanism of MBNL1-AS1. Undoubtedly, the MBNL1-AS1 and the interplay network and the vital roles of MBNL1-AS1 in BC were enriched and verified by this study.

5. Conclusions

We demonstrated that MBNL1-AS1 levels were downregulated in BC tissues, which were correlated with prognosis. In vitro and in vivo assays unravelled the anti-stemness and anti-proliferation roles of MBNL1-AS1. In mechanism, MBNL1-AS1 interacted with ZFP36 and subsequently reduced the stabilization of CENPA mRNA (Figure 5(e)). Therefore, we elucidated a novel mechanism for how MBNL1-AS1 regulated the phenotype of BC and targeting the MBNL1-AS1/ZFP36/CENPA axis might function as therapeutic targets for breast cancer patients.

Data Availability

The data used or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This study was approved by the Ethical Committee of Harbin Medical University. The study was performed according to the ethical standards of Declaration of Helsinki. Additionally, the animal experiments were performed in accordance with the Guide for the Administration of Affairs Concerning Experimental Animals. The study was carried out in compliance with the ARRIVE guidelines.

Consent

Patient informed consent for the use of tissues was obtained prior to the initiation of the study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yu Ding, Yunqiang Duan, and Fei Ma conceived the project; Yingjie Li and Wan Wang acquired and finished analysis of the data; Wei Zheng, Weilun Cheng, Jianyuan Feng, Ziang Chen, Tianshui Yu, Anbang Hu, Ting Wang, Mingcui Li, Hanyu Zhang, and Yanling Li performed the experiments; Baoliang Guo, Fei Ma, and Yu Ding wrote the manuscript. Yu Ding, Yingjie Li, and Yunqiang Duan contributed equally.
Acknowledgments

The work was funded by grants from the National Natural Science Foundation of China (818710121, 8200102587) and the Funds for Distinguished Young Scientists of The Second Affiliated Hospital of Harbin Medical University.

Supplementary Materials

Supplementary Figure 1. The HE-stained tissues of BC and normal. Supplementary Figure 2. The function assays of MCF-7 cells transfected with sh-MBNL1-AS1#2. Supplementary Figure 3. The expression levels of ZFP36 in the BC cells. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” Statistics, vol. 71, pp. 7–33, 2021.
[3] M. D. Brooks, M. L. Burness, and M. S. Wicha, “Therapeutic implications of cellular heterogeneity and plasticity in breast cancer,” Cell Stem Cell, vol. 17, no. 3, pp. 260–271, 2015.
[4] J. E. Visvader and G. J. Lindeman, “Cancer stem cells: current status and evolving complexities,” Cell Stem Cell, vol. 10, no. 6, pp. 717–728, 2012.
[5] T. R. Cech and J. A. Steitz, “The noncoding RNA revolution–trashing old rules to forge new ones,” Cell, vol. 157, pp. 77–94, 2014.
[6] M. Guttman, P. Russell, N. T. Ingolia, J. S. Weissman, and E. S. Lander, “Ribosome profiling provides evidence that large non-coding rnas do not encode proteins,” vol. 154, no. 1, pp. 240–251, 2013.
[7] A. Bhan, M. Soleimani, and S. S. Mandal, “Long noncoding RNA and cancer: a new paradigm,” Cancer Research, vol. 77, no. 15, pp. 3965–3981, 2017.
[8] T. R. Mercer, M. E. Dinger, and J. S. Mattick, “Long non-coding RNAs: insights into functions,” Nature Reviews Genetics, vol. 10, no. 3, pp. 155–159, 2009.
[9] W. L. Hu, L. Jin, A. Xu et al., “GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability,” Nature Cell Biology, vol. 20, no. 4, pp. 492–502, 2018.
[10] T. Tang, C. Guo, T. Xia, R. Zhang, and L. J. T. Jin, “LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling,” Theranostics, vol. 9, no. 24, pp. 7384–7402, 2019.
[11] G. Wang, H. Chen, and J. Liu, “The long noncoding RNA LINC01207 promotes proliferation of lung adenocarcinoma,” American Journal of Cancer Research, vol. 5, no. 10, pp. 3162–3173, 2015.
[12] S. Yu, N. Li, Z. Huang et al., “A novel IncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting repressive activity of ENO1,” Cell Death & Disease, vol. 9, no. 12, p. 1184, 2018.
[13] S. Xu, D. Kong, Q. Chen, Y. Ping, and D. Pang, “Oncogenic long noncoding RNA landscape in breast cancer,” Molecular Cancer, vol. 16, no. 1, p. 129, 2017.
[14] Y. Zhang, J. Sun, Y. Qi et al., “Long non-coding RNA TPT1-AS1 promotes angiogenesis and metastasis of colorectal cancer through TPT1-AS1/NF90/VEGFA signaling pathway,” Aging, vol. 12, no. 7, pp. 6191–6205, 2020.
[15] X. Zang, J. Gu, J. Zhang et al., “Exosome-transmitted IncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression,” Cell Death & Disease, vol. 11, no. 4, p. 215, 2020.
[16] S. G. Zeitlin, “Centromeres: the wild west of the post-genomic age,” Epigenetics, vol. 5, no. 1, pp. 34–40, 2010.
[17] T. Tomonaga, K. Matsushita, S. Yamaguchi et al., “Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer,” Cancer Research, vol. 63, no. 13, pp. 3511–3516, 2003.
[18] G. Ambartsumyan, R. K. Gill, S. D. Perez et al., “Centromere protein A dynamics in human pluripotent stem cell self-renewal, differentiation and DNA damage,” Human Molecular Genetics, vol. 19, no. 20, pp. 3970–3982, 2010.
[19] Y. Li, Z. Zhu, S. Zhang et al., “ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth,” PLoS One, vol. 6, no. 3, article e17794, 2011.
[20] Q. Wu, Y. M. Qian, X. L. Zhao et al., “Expression and prognostic significance of centromere protein A in human lung adenocarcinoma,” Lung Cancer, vol. 77, no. 2, pp. 407–414, 2012.
[21] X. J. Ma, R. Salunga, J. T. Tuggle et al., “Gene expression profiles of human breast cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5974–5979, 2003.
[22] S. L. McGovern, Y. Qi, L. Pusztai, W. F. Symmans, and T. A. Buchholz, “Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer,” Breast Cancer Research, vol. 14, no. 3, pp. 1–11, 2012.
[23] M. R. Green and J. J. C. S. H. P. Sambrook, “Removing DNA Contamination from RNA Samples by Treatment with RNase-Free DNase I,” Cold Spring Harbor Protocols, vol. 2019, no. 10, article pdb.prot101725, 2019.
[24] H. P. Nguyen, P. M. Daniel, G. Filiz, and T. Mantamadiotis, “Investigating neural stem cell and glioma stem cell self-renewal potential using extreme limiting dilution analysis,” Bio-Protocol, vol. 8, no. 17, article e2991, 2018.
[25] F. Ma, H. Song, B. Guo et al., “MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1,” Oncotarget, vol. 6, no. 19, pp. 17404–17416, 2015.
[26] F. Ma, X. Liu, S. Zhou et al., “Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop,” Cancer Letters, vol. 450, pp. 63–75, 2019.
[27] S. Sanduja, F. F. Blanco, L. E. Young, V. Kaza, and D. A. Dixon, “The role of tristetraprolin in cancer and inflammation,” Frontiers in Bioscience: a Journal and Virtual Library, vol. 17, no. 1, pp. 174–188, 2012.
[28] E. Carballo, W. S. Lai, and P. J. Blackshear, “Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA degradation and stability,” Blood, vol. 95, no. 6, pp. 1891–1899, 2000.
[29] G. Cao, B. Tan, S. Wei et al., “Down-regulation of MBLN1-AS1 contributes to tumorigenesis of NSCLC via splicing
miR-135a-5p,” *Biomedicine & Pharmacotherapy*, vol. 125, article 109856, 2020.

[30] P. Li, W. Xing, J. Xu et al., ”microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBLN1-AS1 in non-small cell lung cancer,” *Stem Cells Research & Therapy*, vol. 10, no. 1, p. 144, 2019.

[31] X. Wei, B. Wang, Q. Wang et al., ”MiR-362-5p, which is regulated by long non-coding RNA MBLN1-AS1, promotes the cell proliferation and tumor growth of bladder cancer by targeting QKI,” *Frontiers in Pharmacology*, vol. 11, p. 164, 2020.

[32] X. Wei, X. Yang, B. Wang et al., ”IncRNA MBLN1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer,” *Cancer Medicine*, vol. 9, no. 2, pp. 724–736, 2020.

[33] K. Zhu, Y. Wang, L. Liu, S. Li, and W. Yu, ”Long non-coding RNA MBLN1-AS1 regulates proliferation, migration, and invasion of cancer stem cells in colon cancer by interacting with _MYL9_ via sponging microRNA-412-3p,” *Clinics and Research in Hepatology and Gastroenterology*, vol. 44, no. 1, pp. 101–114, 2020.

[34] L. Xu, S. Zhu, A. Tang, and W. J. I. R. Liu, ”IncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/β-catenin signaling pathway,” *Inflammation Research*, vol. 70, no. 2, pp. 217–227, 2021.

[35] J. C. Wu, S. Z. Luo, T. Liu, L. G. Lu, and M. Y. Xu, ”Inc-SCRG1 accelerates liver fibrosis by decreasing RNA-binding protein tristetrapolin,” *Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology*, vol. 33, no. 2, pp. 2105–2115, 2019.

[36] K. Hua, X. Deng, J. Hu et al., ”Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 39, no. 1, p. 58, 2020.

[37] S. E. Brennan, Y. Kuwano, N. Alkharouf, P. J. Blackshear, M. Gorospe, and G. M. Wilson, ”The mRNA-destabilizing protein tristetrapolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis,” *Cancer Research*, vol. 69, no. 12, pp. 5168–5176, 2009.

[38] E. Hitti, T. Bakheet, N. Al-Souhibani et al., ”Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins,” *Cancer Research*, vol. 76, no. 14, pp. 4068–4080, 2016.

[39] S. Sanduja, V. Kaza, and D. A. Dixon, ”The mRNA decay factor tristetrapolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase,” *Aging*, vol. 1, no. 9, pp. 803–817, 2009.

[40] R. Canzoneri, J. Nairoupe, M. Stedile et al., ”Identification of an AP1-ZFP36 regulatory network associated with breast cancer prognosis,” *Breast Cancer Prognosis*, vol. 25, no. 2, pp. 163–172, 2020.

[41] Q. H. Pan, Y. H. Fan, Y. Z. Wang, D. M. Li, C. E. Hu, and R. X. Li, ”Long noncoding RNA NNT-AS1 functions as an oncogene in breast cancer via repressing ZFP36 expression,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 34, no. 3, pp. 795–805, 2020.

[42] X. Ding, X. Xu, X. F. He, Y. Yuan, and Y. H. J. B. Huang, ”Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/P13K/AKT/mTOR signaling,” *Bioengineered*, vol. 12, no. 1, pp. 803–814, 2021.

[43] D. Xu, Y. Wang, J. Wu et al., ”ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway,” *Cell Death & Disease*, vol. 12, no. 2, pp. 1–15, 2021.

[44] H. A. Kim, J. P. Kim, K. H. Seo, H. K. Lee, and S. Y. J. F. L. Im, ”PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis,” *FEBS Letters*, vol. 586, no. 24, pp. 4296–4302, 2012.

[45] Z. Lin, Y. Lu, Q. Meng et al., ”miR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1,” *Molecular Therapy Nucleic Acids*, vol. 11, pp. 494–507, 2018.

[46] B. Shen, Y. Li, Q. Ye, and Y. J. C. G. T. Qin, ”YY1-mediated long non-coding RNA Kcnq1ot1 promotes the tumor progression by regulating PTEN via DNMT1 in triple negative breast cancer,” *Cancer Gene Therapy*, vol. 28, no. 10, pp. 1099–1112, 2021.

[47] S. Valla, N. Hassan, D. L. Vitale et al., ”Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells. International journal of molecular sciences,” *International Journal Of Molecular Sciences*, vol. 22, no. 11, article 5874, 2021.

[48] C. Liu, H. Wu, Y. Li et al., ”SAL14 suppresses PTEN expression to promote glioma cell proliferation via P13K/AKT signaling pathway,” *Journal of Neuro-Oncology*, vol. 135, no. 2, pp. 263–272, 2017.

[49] S. Kao, K. J. Seo, W. Heo, J. H. Bae, Y. H. J. F. L. Im, and B. R. Communications, ”Cancer upregulated gene 2 (CUG2), a novel oncogene, promotes stemness-like properties via the NPM1-TGF-β signaling axis,” *Biochemical and Biophysical Research Communications*, vol. 514, no. 4, pp. 1278–1284, 2019.

[50] K. Ino, Y. Mitobe, K. Ikeda et al., ”RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8,” *Cancer Science*, vol. 111, no. 1, pp. 148–159, 2020.

[51] J. G. Weinger, W. C. Plaisted, S. M. Maciejewski, L. L. Lanier, C. M. Walsh, and T. E. J. S. C. Lane, ”Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis,” *Stem Cells*, vol. 32, no. 10, pp. 2690–2701, 2014.

[52] J. Wang, S. S. Lou, T. Wang et al., ”UBE3A-mediated PTTP ubiquitination and degradation regulate PPA2 activity and dendritic spine morphology,” *Proceedings of the National Academy of Sciences*, vol. 116, no. 25, pp. 12590–12505, 2019.